Ideaya's conjugate journey continues
The synthetic lethality specialist licenses in its second ADC in six months.
Braftovi outdoes Tafinlar in colorectal cancer
US approval gives Pfizer the first and second-line settings.
Jemperli aims for ovarian white space
But, like Merck two weeks ago, GSK has failed to hit overall survival.
The month ahead: January’s upcoming events
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
Conjugates enter their first clinical trials
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
